14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
COCP vs IMMX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (53.1/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Balance Sheet & Cash Flow), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. COCP trades at $1.01 (N/M Forward P/E, -3063.6% operating margin) versus IMMX at $7.23 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (53.1/100 HOLD vs. COCP 38.7/100 SELL) and 1.83β · 83% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COCP vs IMMX. Trailing 12-month operating profitability (COCP -3063.6% vs IMMX 0.0%) and valuation multiples (COCP N/M vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $657.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ COCP vs IMMX Key Questions & Quantitative Answers
As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (53.1/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Balance Sheet & Cash Flow), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. COCP trades at $1.01 (N/M Forward P/E, -3063.6% operating margin) versus IMMX at $7.23 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (53.1/100 HOLD vs. COCP 38.7/100 SELL) and 1.83β · 83% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
COCP leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, COCP generates $330,000 in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.
COCP screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus IMMX (-27.0% ROE) capital efficiency.
In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 55% Vol realized risk). By comparison, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.83β · 83% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.